ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy

Tobias Klatte; Christian Seitz; Michael Rink; Morgan Rouprêt; Evanguelos Xylinas; Pierre Karakiewicz; Martin Susani; Shahrokh F Shariat

doi:10.1016/j.juro.2015.06.099

ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy

Standard

ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. / Klatte, Tobias; Seitz, Christian; Rink, Michael; Rouprêt, Morgan; Xylinas, Evanguelos; Karakiewicz, Pierre; Susani, Martin; Shariat, Shahrokh F.

in: J UROLOGY, Jahrgang 194, Nr. 5, 07.07.2015, S. 1456-1462.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Klatte, T, Seitz, C, Rink, M, Rouprêt, M, Xylinas, E, Karakiewicz, P, Susani, M & Shariat, SF 2015, 'ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy', J UROLOGY, Jg. 194, Nr. 5, S. 1456-1462. https://doi.org/10.1016/j.juro.2015.06.099

APA

Klatte, T., Seitz, C., Rink, M., Rouprêt, M., Xylinas, E., Karakiewicz, P., Susani, M., & Shariat, S. F. (2015). ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. J UROLOGY, 194(5), 1456-1462. https://doi.org/10.1016/j.juro.2015.06.099

Vancouver

Klatte T, Seitz C, Rink M, Rouprêt M, Xylinas E, Karakiewicz P et al. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. J UROLOGY. 2015 Jul 7;194(5):1456-1462. https://doi.org/10.1016/j.juro.2015.06.099

Bibtex

@article{36ff013463334bcc969a04960b8853d8,

title = "ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy",

abstract = "PURPOSE: ERCC1 is the key enzyme of the nucleotide excision repair pathway, which maintains genomic stability. ERCC1 has been proposed as a prognostic and predictive biomarker for patients with urothelial carcinoma of the bladder but there are limited data on patients after radical cystectomy.MATERIALS AND METHODS: ERCC1 was evaluated by immunohistochemistry in radical cystectomy specimens of 432 patients. Associations with disease-free and cancer specific survival, and the effect of adjuvant cisplatin based chemotherapy were assessed. Further, ERCC1 mRNA expression and in vitro sensitivity to cisplatin were correlated in 25 bladder urothelial carcinoma cell lines.RESULTS: ERCC1 was expressed in 308 tumors (71.3%). There was no association with clinicopathological variables (each p >0.4). Median postoperative followup was 128 months. On multivariable analyses patients with ERCC1 positive tumors had significantly better disease-free survival (HR 0.70, p = 0.028) and cancer specific (HR 0.70, p = 0.032) than those with ERCC1 negative tumors. Discrimination of the multivariable models increased by 0.7% to 0.9% following the inclusion of ERCC1. There was no modification of the effect of adjuvant cisplatin based combination chemotherapy by ERCC1 status (p = 0.38 and 0.88, respectively). There was also no correlation between ERCC1 and sensitivity to cisplatin in vitro (R(2) = 0.02, p = 0.46).CONCLUSIONS: ERCC1 may be a prognostic biomarker for urothelial carcinoma of the bladder. Patients with ERCC1 positive tumors may have better survival than those with ERCC1 negative tumors. However, the efficacy of adjuvant cisplatin based chemotherapy appears to be unrelated to ERCC1 status.",

author = "Tobias Klatte and Christian Seitz and Michael Rink and Morgan Roupr{\^e}t and Evanguelos Xylinas and Pierre Karakiewicz and Martin Susani and Shariat, {Shahrokh F}",

year = "2015",

month = jul,

day = "7",

doi = "10.1016/j.juro.2015.06.099",

language = "English",

volume = "194",

pages = "1456--1462",

journal = "J UROLOGY",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "5",

}

RIS

TY - JOUR

T1 - ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy

AU - Klatte, Tobias

AU - Seitz, Christian

AU - Rink, Michael

AU - Rouprêt, Morgan

AU - Xylinas, Evanguelos

AU - Karakiewicz, Pierre

AU - Susani, Martin

AU - Shariat, Shahrokh F

PY - 2015/7/7

Y1 - 2015/7/7

N2 - PURPOSE: ERCC1 is the key enzyme of the nucleotide excision repair pathway, which maintains genomic stability. ERCC1 has been proposed as a prognostic and predictive biomarker for patients with urothelial carcinoma of the bladder but there are limited data on patients after radical cystectomy.MATERIALS AND METHODS: ERCC1 was evaluated by immunohistochemistry in radical cystectomy specimens of 432 patients. Associations with disease-free and cancer specific survival, and the effect of adjuvant cisplatin based chemotherapy were assessed. Further, ERCC1 mRNA expression and in vitro sensitivity to cisplatin were correlated in 25 bladder urothelial carcinoma cell lines.RESULTS: ERCC1 was expressed in 308 tumors (71.3%). There was no association with clinicopathological variables (each p >0.4). Median postoperative followup was 128 months. On multivariable analyses patients with ERCC1 positive tumors had significantly better disease-free survival (HR 0.70, p = 0.028) and cancer specific (HR 0.70, p = 0.032) than those with ERCC1 negative tumors. Discrimination of the multivariable models increased by 0.7% to 0.9% following the inclusion of ERCC1. There was no modification of the effect of adjuvant cisplatin based combination chemotherapy by ERCC1 status (p = 0.38 and 0.88, respectively). There was also no correlation between ERCC1 and sensitivity to cisplatin in vitro (R(2) = 0.02, p = 0.46).CONCLUSIONS: ERCC1 may be a prognostic biomarker for urothelial carcinoma of the bladder. Patients with ERCC1 positive tumors may have better survival than those with ERCC1 negative tumors. However, the efficacy of adjuvant cisplatin based chemotherapy appears to be unrelated to ERCC1 status.

AB - PURPOSE: ERCC1 is the key enzyme of the nucleotide excision repair pathway, which maintains genomic stability. ERCC1 has been proposed as a prognostic and predictive biomarker for patients with urothelial carcinoma of the bladder but there are limited data on patients after radical cystectomy.MATERIALS AND METHODS: ERCC1 was evaluated by immunohistochemistry in radical cystectomy specimens of 432 patients. Associations with disease-free and cancer specific survival, and the effect of adjuvant cisplatin based chemotherapy were assessed. Further, ERCC1 mRNA expression and in vitro sensitivity to cisplatin were correlated in 25 bladder urothelial carcinoma cell lines.RESULTS: ERCC1 was expressed in 308 tumors (71.3%). There was no association with clinicopathological variables (each p >0.4). Median postoperative followup was 128 months. On multivariable analyses patients with ERCC1 positive tumors had significantly better disease-free survival (HR 0.70, p = 0.028) and cancer specific (HR 0.70, p = 0.032) than those with ERCC1 negative tumors. Discrimination of the multivariable models increased by 0.7% to 0.9% following the inclusion of ERCC1. There was no modification of the effect of adjuvant cisplatin based combination chemotherapy by ERCC1 status (p = 0.38 and 0.88, respectively). There was also no correlation between ERCC1 and sensitivity to cisplatin in vitro (R(2) = 0.02, p = 0.46).CONCLUSIONS: ERCC1 may be a prognostic biomarker for urothelial carcinoma of the bladder. Patients with ERCC1 positive tumors may have better survival than those with ERCC1 negative tumors. However, the efficacy of adjuvant cisplatin based chemotherapy appears to be unrelated to ERCC1 status.

U2 - 10.1016/j.juro.2015.06.099

DO - 10.1016/j.juro.2015.06.099

M3 - SCORING: Journal article

C2 - 26162296

VL - 194

SP - 1456

EP - 1462

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

IS - 5

ER -